Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 3, 2009, Pages 970-975

  Edgerton, Dale S ^a,d   Cherrington, Alan D ^a   Neal, Doss W ^a   Scott, Melanie ^a   Lautz, Margaret ^a   Brown, Nancy ^a   Petro, Jeff ^a   Hobbs, Charles H ^b   Leach, Chet ^b   Del Parigi, Angelo ^c   Strack, Thomas R ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GLUCAGON; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; SOMATOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOG; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIVER METABOLISM; LIVER SINUSOID; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ALGORITHMS; ANIMALS; DIABETES MELLITUS; DOGS; GLUCOSE; HUMANS; INFUSION PUMPS; INSULIN; LIVER; MUSCLE, SKELETAL; RECOMBINANT PROTEINS;

EID: 62449323977     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.146985     Document Type: Article

References (32)

1. Adkins BA, Myers SB, Hendrick GK, Stevenson RW, Williams PE, and Cherrington AD (1987) Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. J Clin Invest 79:557-565.
2. Becker EH, Sha S, Frick AD, and Fountaine RJ (2006) The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 29:277-282.
3. Brain JD, Finch GL, Kiese RJ, Schwartz PF, and Teeter JG (2008) Trough insulin levels in broncho alveolar lavage following inhalation of human insulin (Exubera) in patients with diabetes mellitus. Am J Respir Crit Care Med 177:A618.
4. Cherrington AD, Neal DW, Edgerton DS, Glass D, Bowen L, Hobbs CH, Leach C, Rosskamp R, and Strack TR (2004) Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes 53:877-881.
5. Damas J. Garbacki N, and Lefèbvre PJ (2004) The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 20:288-297.
6. Donmoyer CM, Chen SS, Hande SA, Lacy DB, Ejiofor J, and McGuinness OP (2000) Hyperinsulinemia compensates for infection-induced impairment in net hepatic glucose uptake during TPN. Am J Physiol Endocrinol Metab 279:E235-E243.
7. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumaim WC, Landau BR. Rossetti L, and Cherrington AD (2001) Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50:1872-1882.
8. Edgerton DS, Cherrington AD, Williams P, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Kuo MC, et al. (2006a) Inhalation of human insulin (Exubera) augments the efficiency of muscle glucose uptake in vivo. Diabetes 55:3604-3610.
9. Edgerton DS. Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Sivaku- inaran S, Strack TR, and Cherrington AD (2005) Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54:1164-1170.
10. Edgerton DS, Stettler KM, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Strack TR, and Cherrington AD (2006b) Inhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogs. J Pharmacol Exp Ther 319:1258-1264.
11. Erman A, Chen-Gal B, David I, Giler S, Boner G, and van Dijk DJ (1998) Insulin treatment reduces the increased serum and lung angiotensin converting enzyme activity in streptozotocin-induced diabetic rats. Scand J Clin Lab Invest 58:81-87.
12. Fountaine R, Milton A, Ghecchio T, Wei G, Stolar M, Teeter J, Jaeger R, and Fryburg D (2008) Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol 65:864-870.
13. Galassetti P, Koyama Y, Coker RH, Lacy DB, Cherrington AD, and Wasserman DH (1999) Role of a negative arterial-portal venous glucose gradient in the postexercise state. Am J Physiol 277:E1038-E1045.
14. Galassetti P, Shiota M, Zinker BA, Wasserman DH, and Cherrington AD (1998) A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake. Am J Physiol 275:E101-E111.
15. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, and Much-more DB (2006) Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49:891-899.
16. Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, Liu C, and Krasner A (2005) The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. Diabetes Care 28:2161-2169.
17. Henriksen EJ and Jacob S (2003a) Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 5:214-222.
18. Henriksen EJ and Jacob S (2003b) Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196:171-179.
19. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, and Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890.
20. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, and Adamson U (2004) Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27:162-167.
21. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, and Levin SR (2004) Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2356-2362.
22. Hollander PA, Krasner A, Klioze S, Schwartz P, and Duggan W (2007) Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled phase III trials. Diabetes Care 30:2508-2510.
23. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, and Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473.
24. Krulewitz AH, Baur WE, and Fanburg BL (1984) Hormonal influence on endothelial cell angiotensin-converting enzyme activity. Am J Physiol 247:C163-C168.
25. Moore MC, Hsieh PS, Neal DW, and Cherrington AD (2000) Nonhepatic response to portal glucose delivery in conscious dogs. Am. J Physiol Endocrinol Metab 279: E1271-E1277.
26. Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall M-A, Vesterager A, Wollmer P, and Roberts A (2009) Safety and efficacy of inhaled insulin (AERx®iDMS) compared with subcutaneous insulin therapy in patients with type 1 diabetes one-year data from a randomized, parallel group trial. Diabet Med doi:10.1111/j.1464-5491.2008.02654.x.
27. Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, and Morrow JD (2001) Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem 292:87-93.
28. Patton JS, Bukar JG, and Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781-801.
29. Quattrin T, Bélanger A, Bohannon NJ, and Schwartz SL (2004) Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2622-2627.
30. Rave K, Heise T, Pfützner A, and Boss AH (2007) Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcuta-neously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 30:2307-2308.
31. Sharifi AM, Mousavi SH, and Larijani B (2004) Study of interaction between nitric oxide and ACE activity in STZ-induced diabetic rats: role of insulin. Pharmacol Res 50:261-266.
32. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, and Gerstein HC (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 28:1630-1635.